Bigger Data = Better Data: Detect 7,000 proteins at once with high throughput to optimize biomarker discovery
Abstract
The ideal biomarkers are waiting to be revealed within the human proteome. Big data from many thousands of protein analytes leads to superior biomarker models across therapeutic areas. In this webinar you will discover how machine learning can be harnessed to select the right targets and build the right models for your research. You will also learn how to develop models, identify and mediate clinical risk, and elevate your research with greater precision than ever.
Joe Gogain, PhD
Clinical R&D at SomaLogic
Joe Gogain is a Director of Clinical Research and Development at SomaLogic, Inc., where he works closely with collaborating partners developing diagnostic and prognostic proteomic applications. Joe is a biological scientist with molecular diagnostic and immunoassay development expertise. Joe has a proven track record of IVD product development under design control and experience in de novo 510(k) regulatory submission processes and requirements. Additionally, Joe has served as a director of national clinical trials for point-of-care diagnostic devices and has experience managing a variety of technicians, scientists and clinical operations personnel.
Bigger Data = Better Data: Detect 7,000 proteins at once with high throughput to optimize biomarker discovery
A webinar presented by Joe Gogain, PhD
More webinars
WebinarMapping the human mucosal immune response to respiratory viruses
Conventionally, human immune responses have been extensively characterized using blood. Immune cells, though abundant in blood, are also found in various tissues in varying numbers and with locally relevant functional specification. Assessing immune responses in the airways over the course of infection and convalescence is critical to comprehensively mapping immunity to respiratory viral infections including influenza and SARS-CoV-2.
WebinarAccelerating precision medicine of cancer with SomaScan® proteomics
Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology -- the SomaScan Platform, which measures 7,000 proteins -- to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.
WebinarImproving clinical development productivity with high-plex proteomics
While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete. Assessment of the human proteome is thus increasingly recognized as a priority for successful and cost-effective drug development and clinical research.